Starboard Value LP Shows New 9.8% Stake in DepoMed, Inc. (DEPO); Seeks to Replace Directors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Mizuho Securities Raises Price Target on Depomed (DEPO) Following Starboard's Activism Announcement; Reiterates Neutral
April 11, 2016 7:28 AM EDTMizuho Securities reiterated a Neutral rating on DepoMed Inc (NASDAQ: DEPO), and raised the price target to $18.00 (from $14.00), following Starboard's activism announcement. Mizuho expects the stock to trade in a higher range after Starboard Value disclosed its position in DEPO last week. After... More
Depomed (DEPO) Comments on Starboard Value Stake; Recommends Shareholders Take no Action
April 8, 2016 9:07 AM EDTDepomed, Inc. (Nasdaq: DEPO) issued the following statement in response to the Schedule 13D filed April 7 with the Securities and Exchange Commission by Starboard Value LP:
Depomed welcomes open communications with its shareholders and values constructive input toward... More
Depomed (DEPO) Attracts Activists - Mizuho
April 8, 2016 6:54 AM EDTMizuho analyst, Irina Koffler, noted that activist fund, Starboard Value, has disclosed a 6.8% stake in DepoMed Inc (NASDAQ: DEPO) (but has economic exposure to 9.8% of the outstanding shares). In its 13-D filing, Starboard makes a number of allegations, including: 1) Depomed has serious corporate governance deficiencies; 2) its Board took egregious actions to impede strategic interest from acquiring the company; 3)... More
Starboard Value files 13D on Depomed (DEPO)
April 7, 2016 5:34 PM EDTStarboard Value files 13D on Depomed (NASDAQ: DEPO)
